<DOC>
	<DOCNO>NCT01012193</DOCNO>
	<brief_summary>The purpose study determine impact adjunctive cilostazol versus high maintenance-dose clopidogrel platelet inhibition carrier non-carriers loss-of-function CYP2C19 mutant allele .</brief_summary>
	<brief_title>Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According Cytochrome 2C19 Polymorphism</brief_title>
	<detailed_description>The additional platelet inhibition clopidogrel , thienopyridine inhibitor platelet P2Y12 adenosine diphosphate ( ADP ) receptor , reduce risk ischemic event coronary stent implantation . Because inter-individual variability platelet response clopidogrel , significant proportion suboptimal platelet inhibition report . In addition , persistent residual platelet reactivity measure platelet function test show association cardiovascular outcomes percutaneous coronary intervention ( PCI ) . Various clinical factor genetic polymorphism study predict degree antiplatelet response clopidogrel . Interestingly , recent study find carrier loss-of-function hepatic cytochrome ( CYP ) 2C19 allele significantly low level active metabolite clopidogrel , diminish platelet inhibition , high rate major adverse cardiovascular event non-carriers , set PCI acute coronary syndrome ( ACS ) . These finding raise need solution overcome enhance post-clopidogrel platelet reactivity influence loss-of-function CYP2C19 allele . Increasing dose clopidogrel new potent P2Y12 antagonist ( prasugrel ) may alternative antiplatelet regimen patient loss-of-function CYP variant . Cilostazol reversibly induce platelet inhibition via blockade phosphodiesterase ( PDE ) type 3 catalyse mainly CYP3A . A recent study demonstrate adjunctive cilostazol dual antiplatelet therapy ( triple antiplatelet therapy ) intensify platelet inhibition compare high maintenance-dose ( MD ) 150 mg/day . Therefore , triple antiplatelet therapy could also alternative antiplatelet therapy improve platelet inhibition clinical outcome carrier CYP2C19 mutant allele . We compare enhance inhibition platelet aggregation adjunctive cilostazol 100 mg twice daily versus high-MD clopidogrel 150 mg/day patient treat elective coronary stenting , accord CYP2C19 polymorphism .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Significant coronary artery stenosis ( &gt; 70 % visual estimate ) Elective coronary stent implantation Acute myocardial infarction Active bleeding bleeding diatheses Hemodynamic instability Oral anticoagulation therapy warfarin Use periprocedural glycoprotein IIb/IIIa inhibitor Contraindication antiplatelet therapy Left ventricular ejection fraction &lt; 30 % Leukocyte count &lt; 3,000/mm3 , platelet count &lt; 100,000/mm3 , AST ALT ≥ 3 time upper normal Serum creatinine level ≥ 3 mg/dL Stroke within 3 month Noncardiac disease life expectancy &lt; 1 year Inability follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>adjunctive cilostazol</keyword>
	<keyword>high-MD clopidogrel</keyword>
	<keyword>CYP 2C19 polymorphism</keyword>
	<keyword>high risk patient</keyword>
</DOC>